Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in proteomics dealmaking

2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Deal terms for proteomics partnering
2.6.1 Proteomics partnering headline values
2.6.2 Proteomics deal upfront payments
2.6.3 Proteomics deal milestone payments
2.6.4 Proteomics royalty rates


Chapter 3 – Leading proteomics deals

3.1. Introduction
3.2. Top proteomics deals by value

Chapter 4 – Most active proteomics dealmakers

4.1. Introduction
4.2. Most active proteomics dealmakers
4.3. Most active proteomics partnering company profiles

Chapter 5 – Proteomics contracts dealmaking directory

5.1. Introduction
5.2. Proteomics contracts dealmaking directory

Chapter 6 – Proteomics dealmaking by technology type

Appendices

Appendix 1 – Proteomics deals by company A-Z
Appendix 2 – Proteomics deals by stage of development
Appendix 3 – Proteomics deals by deal type
Appendix 4 – Proteomics deals by therapy area
Deal type definitions
Further reading

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
?
Table of figures

Figure 1: Proteomics partnering since 2010
Figure 2: Active proteomics dealmaking activity sincce 2010
Figure 3: Proteomics partnering by deal type since 2010
Figure 4: Proteomics partnering by disease type since 2010
Figure 5: Proteomics partnering by industry sector since 2010
Figure 6: Proteomics deals with a headline value
Figure 7: Proteomics deals with an upfront value
Figure 8: Proteomics deals with a milestone value
Figure 9: Proteomics deals with a royalty rate value
Figure 10: Top proteomics deals by value since 2010
Figure 11: Most active proteomics dealmakers since 2010
Figure 12: Proteomics partnering by technology type since 2010